<DOC>
	<DOCNO>NCT00367770</DOCNO>
	<brief_summary>This 6-month open label study evaluate long term safety bosentan ( via oxygen saturation ) efficacy ( exercise capacity ) patient complete BREATHE-5 study ( PAH relate Eisenmenger physiology ) . Treatment duration 6 month .</brief_summary>
	<brief_title>BREATHE 5-OL : Tracleer ( Bosentan ) Patients With Pulmonary Arterial Hypertension Related Eisenmenger Physiology</brief_title>
	<detailed_description>This multicenter , open-label , single -arm study bosentan , initial dose 62.5 mg b.i.d. , target dose 125 mg b.i.d . All patient assess eligibility baseline visit ( Week 16 , end study BREATHE-5 visit ) , option enter open-label extension study start dose 62.5 mg b.i.d. , safety reason . Visit 2 require safety visit ass oxygen saturation ( SpO2 ) 1 week bosentan treatment . Patients return Visit 4 4 week treatment , dose up-titrated 125 mg b.i.d . maintain 62.5 mg b.i.d . judgement investigator . Data collect total 24 week sponsor decide stop study . If result Study AC-052-403 AC-052-405 demonstrate significant safety issue , extension study may terminate sponsor 's request .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Eisenmenger Complex</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>1 . Patients stable PAH upon completion BREATHE5 randomize , doubleblind , placebo control 16week study . 2 . For female patient , nonpregnant woman surgically sterile , postmenopausal document infertility ( 50 year age amenorrheic least 1 year ) , childbearing potential use one follow method contraception : Barriertype device ( e.g. , condom , diaphragm ) use ONLY combination spermicide . A doublebarrier method recommend ; intrauterine device ( IUDs ) ; oral implanted contraceptive , use combination barrier method . 3 . Patients provide write informed consent . 1 . Patients withdraw prematurely BREATHE5 , AC052405 . 2 . Patients pregnant nursing . 3 . Patients receive epoprostenol prostacyclin analogue , expect receive drug study . 4 . Patients AST and/or ALT value great 3 time upper limit normal . 5 . Patients hemoglobin hematocrit 30 % normal range ( patient secondary polycythemia permit study ) . 6 . Patients systolic blood pressure &lt; 85 mm Hg . 7 . Patients take phosphodiesterase inhibitor , endothelin receptor antagonist receive another investigational product . 8 . Patients active organ transplant list . 9 . Patients receive expect receive glyburide , cyclosporin A tacrolimus . 10 . Patients able comply protocol adhere therapy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>bosentan</keyword>
	<keyword>PAH related Eisenmenger physiology</keyword>
	<keyword>Tracleer</keyword>
</DOC>